

SUMMARY

latanoprost

LIFOG 50 µg/ml

eye drops solution

Inclusion on list: First listing

Hybrid

Adopted by the Transparency Committee on 25 September 2024

Summary of opinion

Favourable opinion for reimbursement in the MA indications: "Reduction of elevated intraocular pressure in patients with open angle glaucoma and ocular hypertension.

Reduction of elevated intraocular pressure in paediatric patients with elevated intraocular pressure and paediatric glaucoma."

No clinical added value compared to the reference medicinal product, XALATAN (latanoprost) 50 µg/ml eye drops solution.

Transparency Committee's conclusions**Clinical Benefit**

- Glaucoma is a severe condition that can cause blindness.
- This proprietary medicinal product is a curative treatment for elevated intraocular pressure and a preventive treatment for complications of the condition.
- The efficacy/adverse effects ratio is high.
- This product is a first-line treatment in the same way as other prostaglandin analogues.

This document and its bibliographic reference are available to download at www.has-sante.fr 

This opinion is published subject to intellectual property rights

Haute Autorité de Santé – Communication and Information Department

5 avenue du Stade de France – 93218 SAINT-DENIS LA PLAINE CEDEX – France. Tel.: +33 (0)1 55 93 70 00

© Haute Autorité de santé – September 2024

→ Public health benefit

LIFOG (latanoprost) 50 µg/ml eye drops solution is unlikely to have an additional impact on public health compared to the reference medicinal product, XALATAN 50 µg/ml (latanoprost) eye drops solution.

The Committee considers that the clinical benefit of LIFOG (latanoprost) 50 µg/ml eye drops solution is substantial in the MA indications.

The Committee issues a favourable opinion for inclusion in both the list of covered drugs for outpatients and the list of covered drugs for inpatients approved for use in the MA indications and dosages.

→ Recommended reimbursement rate for inclusion in the list of covered drugs for outpatients: 65%

Clinical Added Value

This medicinal product is a hybrid that does not provide any clinical added value (CAV V) compared to the reference medicinal product, XALATAN 50 µg/ml (latanoprost) eye drops solution.